EVALUATING THE EFFECT OF LIPID-APHERESIS ON EVINACUMAB AND ANGIOPOIETIN-LIKE 3 (ANGPTL3) LEVELS

被引：0

作者：

Moriarty, P. M. ^{[1
]}

Dutton, J. -A. ^{[2
]}

Gorby, L. ^{[1
]}

Vance, J. ^{[2
]}

Ali, S. ^{[3
]}

Zhao, A. ^{[4
]}

Khilla, N. ^{[4
]}

Alejandro, M. ^{[4
]}

Rodriguez, J. ^{[4
]}

Rajadhyaksha, M. ^{[4
]}

Andisik, M. ^{[4
]}

Gipe, D. A. ^{[3
]}

Zhang, Y. ^{[5
]}

机构：

[1] Univ Kansas, Med Ctr, Div Clin Pharmacol, Dept Internal Med, Kansas City, KS 66103 USA

[2] Univ Kansas, Med Ctr, Atherosclerosis & Ldlapheresis Ctr, Kansas City, KS 66103 USA

[3] Regeneron Pharmaceut Inc, Cardiovasc & Metab Therapeut, New York, NY USA

[4] Regeneron Pharmaceut Inc, Bioanalyt Sci, New York, NY USA

[5] Regeneron Pharmaceut Inc, Clin Pharmacol, New York, NY USA

来源：

ATHEROSCLEROSIS | 2020年 / 315卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1386

引用

页码：E37 / E37

页数：1

共 50 条

[1] Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects
Lupo, Maria Giovanna
Ferri, Nicola
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2018, 5 (03)
[2] Atypical angiopoietin-like protein that regulates ANGPTL3
Quagliarini, Fabiana
Wang, Yan
Kozlitina, Julia
Grishin, Nick V.
Hyde, Rhonda
Boerwinkle, Eric
Valenzuela, David M.
Murphy, Andrew J.
Cohen, Jonathan C.
Hobbs, Helen H.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (48) : 19751 - 19756
[3] Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3) -: ANGPTL3 is cleaved and activated in vivo
Ono, M
Shimizugawa, T
Shimamura, M
Yoshida, K
Noji-Sakikawa, C
Ando, Y
Koishi, R
Furukawa, H
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (43) : 41804 - 41809
[4] Evaluation of angiopoietin-like protein 3 (ANGPTL3) levels in polycystic ovary syndrome
Vatannejad, Akram
Salimi, Fouzieh
Moradi, Nariman
Fouani, Fatima Zahraa
Zandieh, Zahra
Ansaripour, Soheila
Sadeghi, Asie
Fadaei, Reza
LIFE SCIENCES, 2020, 263
[5] SAFETY, TOLERABILITY AND PHARMACOKINETICS OF EVINACUMAB, AN ANGIOPOIETIN-LIKE PROTEIN 3 (ANGPTL3) INHIBITOR, IN HEALTHY JAPANESE AND CAUCASIAN SUBJECTS
Harada-Shiba, M.
Ali, S.
Gipe, D. A.
Gasparino, E.
Son, V.
Pordy, R.
Catapano, A. L.
ATHEROSCLEROSIS, 2020, 315 : E36 - E37
[6] Structure and Function of Angiopoietin-like Protein 3 (ANGPTL3) in Atherosclerosis
Lu, Xinjie
CURRENT MEDICINAL CHEMISTRY, 2020, 27 (31) : 5159 - 5174
[7] Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia
Tarugi, Patrizia
Bertolini, Stefano
Calandra, Sebastiano
JOURNAL OF BIOMEDICAL RESEARCH, 2019, 33 (02): : 73 - 81
[8] Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia
Chen, Pei-Yi
Gao, Wan-Yun
Liou, Je-Wen
Lin, Ching-Yen
Wu, Ming-Jiuan
Yen, Jui-Hung
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (14)
[9] Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia
Patrizia Tarugi
Stefano Bertolini
Sebastiano Calandra
TheJournalofBiomedicalResearch, 2019, 33 (02) : 73 - 81
[10] Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia
Kosmas, Constantine E.
Bousvarou, Maria
Sourlas, Andreas
Papakonstantinou, Evangelia J.
Genao, Edilberto Pella
Uceta, Rogers Echavarria
Guzman, Eliscer
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2022, 14 : 49 - 59

← 1 2 3 4 5 →